BrainStorm announced the promotion of Dr. Stacy Lindborg to the role of Co-CEO. This promotion launches a targeted capability build which will be led by Dr. Lindborg, to hire and bring expertise inside BrainStorm, preparing for success. Dr. Lindborg, who joined BrainStorm in 2020 and is based in the U.S., brings to her expanded role more than 25 years of pharmaceutical industry experience in R&D, strategy development, regulatory, and analytics. She will work alongside Chaim Lebovits, who is retaining his position as President and CEO. In addition, Dr. Ralph Kern will retire from his current role as President and Chief Medical Officer in January 2023 and will continue to support BrainStorm as part of the company’s Scientific Advisory Board.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BCLI:
- BrainStorm announces Type A meeting with FDA granted for NurOwn
- BrainStorm submits Type A Meeting Request to U.S. FDA
- BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update
- BrainStorm reports Q3 EPS (53c), two estimates (18c)
- Brainstorm Plummets After the FDA Rejects Application